newsfilter
← Latest News
Business Wire·

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - -